‘A rising tide scenario’: Why other Big Pharmas could follow Lilly into psychedelics

After Eli Lilly dived into the psychedelics space with a $2.8 billion upfront acquisition of AtaiBeckley last week, industry experts told Fierce that the deal would give the space added momentum.